Skip to main content
Videos

Addition of Docetaxel to FOLFOX/CAPOX Backbone Fails to Improve OS in Advanced GEJ/Gastric Cancer

Featuring Anant Ramaswamy, MD


Anant Ramaswamy, MD, Tata Memorial Hospital, Mumbai, India, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced gastroesophageal junction (GEJ) and gastric cancers.

Dr Ramaswamy presented these results at the 2024 ASCO Gastrointestinal Cancers Symposium in San Francisco, California.


Source:

Ramaswamy A, Bhargava PB, Dubashi B, et al. A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers (DOC-GC study). Presented at 2024 ASCO Gastrointestinal Cancer Symposium; January 18-20, 2024; San Francisco, California. Abstract LBA248.

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.